InnoPharmax Inc. (TPEX:4172)

Market Cap	1.69B
Revenue (ttm)	32.30M
Net Income (ttm)	-99.29M
Shares Out	107.58M
EPS (ttm)	-1.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,934
Average Volume	373,932
Open	15.30
Previous Close	15.30
Day's Range	15.30 - 15.75
52-Week Range	11.20 - 29.25
Beta	0.49
RSI	53.75
Earnings Date	Apr 18, 2025

About InnoPharmax

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company’s core products include N11005, a prandial oral insulin; and GemOral. It also offers Imipenem and Cilastatin solution for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents consisting of gadopentetate dimeglumine and gadodiamide; oncology age...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 34
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4172

Financial Performance

In 2024, InnoPharmax's revenue was 32.30 million, a decrease of -29.90% compared to the previous year's 46.07 million. Losses were -99.29 million, 40.2% more than in 2023.